2 recruiting. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) Fenebrutinib - Relapsing Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 12 | 2025-10-06 | 2026-10-13 |
Fingolimod Hydrochloride (1) · fenebrutinib (1) · ublituximab (1)
Hoffmann-La Roche (1) · TG Therapeutics, Inc. (1)
Poland (2) · Argentina (1) · Brazil (1) · Mexico (1) · Portugal (1) · Slovakia (1) · Spain (1) · Ukraine (1) · United States (1)
2025 (1)